Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects

2021 ◽  
Author(s):  
Soo Lim ◽  
Minji Sohn ◽  
Yujin Shin ◽  
Ele Ferrannini
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Effects ◽  
Drug Naïve ◽  
Initial Combination

Initial Combination Therapy with Metformin plus Colesevelam in Drug-Naïve Hispanic Patients with Early Type 2 Diabetes

2012 ◽  
Vol 124 (4) ◽  
pp. 7-13 ◽  
Author(s):  
Julio Rosenstock ◽  
Eric Hernandez-Triana ◽  
Yehuda Handelsman ◽  
Soamnauth Misir ◽  
Michael R. Jones ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Early Type ◽  
Initial Combination Therapy ◽  
Hispanic Patients ◽  
Drug Naïve ◽  
Initial Combination

scholarly journals Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes

Diabetes Care ◽  
2010 ◽  
Vol 33 (11) ◽  
pp. 2406-2408 ◽  
Author(s):  
J. Rosenstock ◽  
S. E. Inzucchi ◽  
J. Seufert ◽  
P. R. Fleck ◽  
C. A. Wilson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Initial Combination Therapy ◽  
Drug Naïve ◽  
Initial Combination

scholarly journals Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes

Diabetes Care ◽  
2016 ◽  
Vol 39 (3) ◽  
pp. 353-362 ◽  
Author(s):  
Julio Rosenstock ◽  
Leonard Chuck ◽  
Manuel González-Ortiz ◽  
Kate Merton ◽  
Jagriti Craig ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Initial Combination Therapy ◽  
Drug Naïve ◽  
Initial Combination

Abstract #203 The Real Life Effectiveness; Metabolic Effects and Tolerability of Hydroxychloroquine Once Daily in the Treatment of Type-2 Diabetes Mellitus

2018 ◽  
Vol 24 ◽  
pp. 28-29
Author(s):  
Hemant Thacker ◽  
Rupal Shrimanker ◽  
Banshi Saboo ◽  
Diabetologist ◽  
Anuj Maheshwari ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real Life ◽  
Metabolic Effects ◽  
Life Effectiveness ◽  
Once Daily ◽  
The Real

Is it time for initial combination in type 2 diabetes? - AGAINST

2017 ◽  
Author(s):  
Didac Mauricio
Keyword(s):  
Type 2 Diabetes ◽  
Initial Combination

Metformin: Up to Date

2020 ◽  
Vol 20 (2) ◽  
pp. 172-181 ◽  
Author(s):  
Silvia Sciannimanico ◽  
Franco Grimaldi ◽  
Fabio Vescini ◽  
Giovanni De Pergola ◽  
Massimo Iacoviello ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Current Literature ◽  
Weight Control ◽  
Low Cost ◽  
Hepatic Glucose Production ◽  
Metabolic Effects ◽  
Hypoglycemic Agents ◽  
Positive Effects ◽  
Mesh Terms

Background: Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes. It improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscles. Metformin improves insulin sensitivity and shows a beneficial effect on weight control. Besides its metabolic positive effects, Metformin has direct effects on inflammation and can have immunomodulatory and antineoplastic properties. Aim: The aim of this narrative review was to summarize the up-to-date evidence from the current literature about the metabolic and non-metabolic effects of Metformin. Methods: We reviewed the current literature dealing with different effects and properties of Metformin and current recommendations about the use of this drug. We identified keywords and MeSH terms in Pubmed and the terms Metformin and type 2 diabetes, type 1 diabetes, pregnancy, heart failure, PCOS, etc, were searched, selecting only significant original articles and review in English, in particular of the last five years. Conclusion: Even if many new effective hypoglycemic agents have been launched in the market in the last few years, Metformin would always keep a place in the treatment of type 2 diabetes and its comorbidities because of its multiple positive effects and low cost.

Sign in / Sign up

Export Citation Format

Share Document